Tractament farmacològic de la malaltia d’Alzheimer: informe d’avaluació de resultats del Registre de tractament farmacològic de la malaltia d’Alzheimer
Abstract
The Register of Pharmacological Treatment of Alzheimer’s Disease (RTFMA) for people diagnosed with Alzheimer’s Disease (AD), implemented in 2011, is a computer application linked to the Integrated Electronic Prescription System (SIRE). The RTFMA is used for the automatic validation of the dispensing of treatments for the Alzheimer’s disease. Personal, clinical, and treatment data prescribed to patients should be included as a necessary condition for the validation and dispensing of drugs at the start of treatment. The validity of the treatment lasts 24 months, and then it is necessary to request its renewal. The results are collected using the global deterioration scale (GDS-FAST, possible values between 1 and 7 where 7 is the worst deterioration; within 6 there are 5 degrees of severity ranging from A to E, and within the 7 six more degrees ranging from A to F). The Minimental test (Mini-Mental State Examination [MMSE], values between 0 and 30, where the lowest values indicate the worst deterioration) is also included, although for simplicity they are not included in this summary. The RTFMA contains relative information on prescriptions for acetylcholinesterase inhibitor (IACE) drugs and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists since 2012.
Keywords
Alzheimer; Pharmacological treatment; Pharmacological treatment of Alzheimer's disease
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tractament farmacològic de la malaltia d’Alzheimer: informe d’avaluació de resultats del Registre de tractament farmacològic de la malaltia d’Alzheimer. Barcelona: Servei Català de la Salut; 2018.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/6533This item appears in following collections
The following license files are associated with this item: